Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA

8 Oct 2015

Abstract excerpt

// Jiang-Jiang Qin 1, 2, * , Wei Wang 1, 2, * , Sukesh Voruganti 1 , Hui Wang 3 , Wei-Dong Zhang 4 , Ruiwen Zhang 1, 2 1 Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA 2 Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA 3 Institute for Nutritional Sciences, Shanghai Institutes for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors
Share to Signaling Pathways in Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26461225
DOI: 10.18632/oncotarget.5851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapAPMID 26461225Read ↗

Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validationSemantic proximity Read ↗

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapySemantic proximity Read ↗

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and AndrogenSemantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of ViewSemantic proximity Read ↗

Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.Semantic proximity Read ↗

PPM1D, a Promising Therapeutic Target Uncovered Through shRNA Library Screening, Plays a Pivotal Role in Regulating the Progression of Breast CancerSemantic proximity Read ↗

The agonist of JWA gene JAC1 suppresses proliferation of breast cancer through JWA/p38/SMURF1/HER2 signalingSemantic proximity Read ↗

Targeting MDM2-p53 interaction for breast cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.